Get the Stockscreener App
114.64
0.61%
0.695
After Hours:
114.64
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $114.64, with a volume of 331.08K.
It is up +0.61% in the last 24 hours and up +2.76% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$113.94
Open:
$112.06
24h Volume:
331.08K
Relative Volume:
2.87
Market Cap:
$2.17B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
79.61
EPS:
1.44
Net Cash Flow:
$6.97M
1W Performance:
-1.94%
1M Performance:
+2.76%
6M Performance:
+43.64%
1Y Performance:
+65.35%
1-Day Range:
$111.00
$115.47
1-Week Range:
$111.00
$124.03
52-Week Range:
$67.53
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
114.64 | 2.17B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Wellington Management Group LLP Trims Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
What is Zacks Small Cap's Forecast for LGND FY2025 Earnings? - MarketBeat
Zacks Small Cap Has Strong Estimate for LGND FY2026 Earnings - MarketBeat
Fmr LLC Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals: A Strong Growth Trajectory with Impressive Returns and Strategic Advancements - mediahousepress
LGND: 2025 View Calls for 17% Topline Growth - Zacks Small Cap Research
Ligand Pharmaceuticals' SWOT analysis: diversified royalty model drives stock growth - Investing.com Australia
Barclays Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $160.00 - MarketBeat
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Ligand Pharmaceuticals' SWOT analysis: royalty aggregator stock poised for growth - Investing.com
What is HC Wainwright's Estimate for LGND FY2025 Earnings? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,031 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand price target raised to $151 from $135 at Oppenheimer - Yahoo Finance
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews - Benzinga
Ligand Pharmaceuticals' (LGND) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Ligand forecasts revenue growth and higher earnings for 2025 By Investing.com - Investing.com Canada
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance - BioSpace
5,961 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Purchased by Verition Fund Management LLC - MarketBeat
Ligand forecasts revenue growth and higher earnings for 2025 - Investing.com
Ligand Pharmaceuticals Investor And Analyst Day At 10:30 AM ET - Nasdaq
Ashford Capital Management Inc. Sells 11,800 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Charles Schwab Investment Management Inc. Has $16.41 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Erste Asset Management GmbH Purchases Shares of 4,300 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Insiders Sell US$6.3m Of Stock, Possibly Signalling Caution - Simply Wall St
RBC upgrades Ligand Pharma shares target ahead of guidance report By Investing.com - Investing.com Canada
RBC upgrades Ligand Pharma shares target ahead of guidance report - Investing.com
John L LaMattina At Ligand Pharmaceuticals Executes Options Exercise, Realizing $169K - Benzinga
Ligand Pharmaceuticals director John LaMattina sells $297,501 in stock By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals director John LaMattina sells $297,501 in stock - Investing.com
LGND (Ligand Pharmaceuticals) Shares Outstanding (EOP) : 18.8 Mil (As of Sep. 2024) - GuruFocus.com
34,069 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Bought by Edgestream Partners L.P. - MarketBeat
Isthmus Partners LLC Sells 9,622 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Fisher Asset Management LLC Purchases 6,555 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Loomis Sayles & Co. L P Buys 114,436 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Victory Capital Management Inc. - MarketBeat
Ligand Pharmaceuticals (FRA:LGDN) Inventories, Finished Goo - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Analysts Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Target Price at $144.83 - MarketBeat
Ligand Pharmaceuticals' SWOT analysis: stock's growth potential in focus - Investing.com India
Royce & Associates LP Has $610,000 Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals (STU:LGDN) Future 3-5Y EPS without N - GuruFocus.com
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings - Yahoo Finance
Janus Henderson Group PLC Expands Stake in Ligand Pharmaceuticals Inc - GuruFocus.com
Ligand Pharmaceuticals to Present at Stifel 2024 Healthcare Conference | LGND Stock News - StockTitan
Royal Bank of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $150.00 Price Target at Barclays - Defense World
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ligand Pharmaceuticals Inc Stock (LGND) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LAMATTINA JOHN L | Director |
Nov 27 '24 |
Sale |
123.65 |
2,406 |
297,502 |
29,515 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):